Migraine and endometriosis may coexist considerably more frequently than routine healthcare records suggest, according to a meta-analysis involving more than 13 million women. The findings, presented at the 2026 American Neurological Association Annual Meeting, highlight the potential under-recognition of overlapping symptoms and the importance of coordinated neurological and gynaecological care.
Researchers analysed 35 studies spanning 50 years, involving 207,675 women with endometriosis and 12,963,120 controls. Women with endometriosis had 2.3 times the odds of migraine compared with those without the condition (95% CI 1.75–3.05).
The most striking finding concerned differences in migraine identification. Specialist clinic interviews reported migraine in 54% to 78% of women with endometriosis, compared with 17.8% to 42.8% in longer-term insurance records and fewer than 5% in one-year billing records.
| Sign up to the ACNR email newsletter here |
Researchers suggest that short-term administrative records could therefore miss up to 90% of cases involving both conditions.
However, the association itself is not new. A systematic review published in The Journal of Headache and Pain in April 2025, involving 331,655 individuals, reported similarly elevated odds of migraine (OR 2.25). An earlier meta-analysis by the Mayo Clinic researchers, presented in June 2025, also identified substantial comorbidity.
The latest analysis extends this evidence by examining how different methods of recording diagnoses influence reported prevalence.
Substantial between-study heterogeneity means the findings require cautious interpretation. Differences between specialist clinic populations and administrative datasets may contribute to the apparent under-reporting.
The researchers also highlight calcitonin gene-related peptide (CGRP) signalling as a possible shared mechanism involving neuroinflammation and pain sensitisation.
Although this raises interest in investigating CGRP-targeting migraine therapies for endometriosis-associated pain, clinical trials are needed before any therapeutic benefit can be established. The potential is sufficiently promising that researchers at Mayo Clinic have secured funding for a Phase II clinical trial of rimegepant, an established migraine treatment, in women with endometriosis.
The study will investigate whether blocking CGRP can reduce endometriosis-related pelvic pain, potentially opening the door to a new non-hormonal treatment approach. See https://clinicaltrials.gov/study/NCT07795125?
The findings reinforce the value of asking patients with migraine about severe menstrual symptoms and chronic pelvic pain. Greater awareness of this association could improve recognition, facilitate appropriate gynaecological referral and support more integrated management.
This news item has been summarised using AI and checked by humans before publication.
| Join our online community for neurology specialists |
Sources
- American Neurological Association, 20 October 2026: Migraine, Endometriosis Overlap Far More Than Recognized, Analysis of 13 Million Finds
- The Journal of Headache and Pain, 17 April 2025: The association between endometriosis and migraine: a systematic review and meta-analysis of observational studies
- American Headache Society, June 2025: 67th Annual Scientific Meeting abstracts, P-355: High comorbidity between endometriosis and migraine: A comprehensive meta-analysis
